Article Text

Download PDFPDF

121 Comparison of clinical and laboratory profiles in 3575 systemic lupus erythematosus patients with and without Sjögrens syndrome: data from the spanish society for rheumatology lupus registry
  1. Juan Ovalles-Bonilla1,
  2. Jose Maria Pego Reigosa2,
  3. Iñigo Rua Figueroa3,
  4. Maria Galindo Izquierdo4,
  5. Jaime Calvo-Alén5,
  6. Juan Carlos Nieto1,
  7. Julia Martínez-Barrio1,
  8. Roberto González1,
  9. Belen Serrano1,
  10. Iustina Janta1,
  11. Carlos M Gonzalez1,
  12. Indalecio Monteagudo1,
  13. Javier Narváez-García6,
  14. José Luis Andréu-Sánchez7,
  15. Mireia Moreno-Martínez-Losa8,
  16. Ana Sánchez-Atrio9,
  17. Loreto Horcada10,
  18. Tatiana Cobo-Ibáñez11,
  19. Carlos Marras-Fernández-Cid12,
  20. Eva Salgado-Pérez13,
  21. Juan J Alegre-Sancho14 and
  22. Francisco Javier López-Longo1
  1. 1Hospital General Universitario Gregorio Marañón
  2. 2Complexo hospitalario Universitario Vigo
  3. 3Hospital de Gran Canaria dr. Negrín
  4. 4Hospital Universitario 12 De Octubre
  5. 5Hospital Universitario Araba
  6. 6Bellvitge University Hospital, Barcelona
  7. 7Hospital Universitario Puerta de Hierro
  8. 8Hospital Parc Taulí
  9. 9Hospital Príncipe De Asturias
  10. 10Complejo Hospitalario de Navarra
  11. 11Hospital Infanta Sofía
  12. 12Hospital Virgen De La Arrixaca
  13. 13Complejo Hospitalario de Ourense
  14. 14Hospital dr. Peset


Background The clinical coexistence of Systemic Lupus Erythematosus (SLE) and Sjögrens Syndrome (SS) was recognized in 1959. The prevalence of SS among patients with SLE varies considerably among the published studies (10%–30%). There is still controversy as to whether or not SLE patients with overlapping SS have a distinct and significantly milder lupus. To address the clinical and serologic features of SLE and differences from SLE that occurs in overlap with SS.

Methods This is a multicenter, descriptive, cross-sectional study of 3575 patients from the Spanish Society for Rheumatology Lupus Registry (RELESSER). Unselected SLE patients from 45 Rheumatology Departments across Spain were evaluated for the presence of overlapping SS using the American-European consensus criteria. Cumulative clinical data were collected at the moment of the last assessment. Clinical and laboratory parameters in SLE patients with SS (SLEwSS) were compared with those in SLE patients without SS (SLEwoSS).

Results SS was identified in 516 SLE patients (14.4%). Compared with the SLEwoSS group, patients with SLEwSS were significantly older, had a higher frequency of mucocutaneous manifestations, Raynauds phenomenon, peripheral neuropathy, anti-Ro/SSA, anti-La/SSB, neoplasia, and older age at death, but had a significantly lower frequency of renal involvement, thrombocytopenia, anti-dsDNA, anti-2-GPI IgM and complement consumption. Both groups displayed a clinically similar presentation of lymphadenopathy, systemic vasculitis, serositis, damage accrual, mortality, musculoskeletal and CNS manifestations.

Abstract 121 Table 1

Conclusions SLEwSS appears to constitute a subgroup of SLE patients with distinct clinical and serologic features, in whom SS is expressed as an overlapping entity. A particular cluster of clinical variables, namely, mucocutaneous manifestations, Raynauds phenomenon, peripheral neuropathy, renal involvement and thrombocytopenia, was found to be important overall for discriminating SLE patients with or without SS. SLEwSS patients constitute a subgroup of patients with SLE characterized by milder lupus: older age at death, similar rates of mortality and SLICC-ACR damage index, less renal and immunological manifestations.

Funding Source(s): None

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.